FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2240-2242 May 26, 2005 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Over the past two decades, the cataloguing of mutated oncogenes and tumor-suppressor genes in various types of human cancers has provided a rich knowledge base for the creation of genetic models. Although powerful in terms of their ability to elucidate gene function in a controlled environment in vivo, these models are prone to the perils of biologic reductionism. Often missed are the boilerplate goals of mimicking a particular human cancer sufficiently to render insight into the early natural history of the disease process and providing a relevant preclinical tool for testing therapies. Ovarian carcinoma has proved exceptionally refractory to genetic . . . [Full Text of this Article]

Source Information

From the Departments of Medicine and Surgery, Memorial Sloan-Kettering Cancer Center, New York.

This article has been cited by other articles:

• Becker, C. M., Wright, R. D., Satchi-Fainaro, R., Funakoshi, T., Folkman, J., Kung, A. L., D'Amato, R. J. (2006). A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy. Am. J. Pathol. 168: 2074-2084 [Abstract] [Full Text]